Top FDA approval stories in allergy/asthma for 2021
Click Here to Manage Email Alerts
Allergy and asthma treatment improved this year as the FDA approved multiple medications for new treatment. Here are the top developments for 2021 as reported by Healio.
The FDA approved mepolizumab (Nucala, GlaxoSmithKline) as a treatment for adults who have chronic rhinosinusitis with nasal polyps. Read more.
The FDA approved ruxolitinib (Opzelura, Incyte) as a topical atopic treatment for atopic dermatitis for non-immunocompromised patients. Read more.
The FDA approved tezepelumab (Tezspire, Amgen/AstraZeneca) for add-on maintenance treatment of adults and children aged 12 years and older with severe asthma. Read more.
The FDA approved cutaquig (Octapharma) for the treatment of children aged 2 years and older with primary humoral immunodeficiency. Read more.
The FDA approved dupilumab (Dupixent, Regeneron/Sanofi) as add-on maintenance treatment for children aged 6 to 11 years with moderate to severe asthma characterized by an eosinophilic phenotype or with oral corticosteroid-dependent asthma. Read more.